Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus.

E A Emini, S D Putney

    Biotechnology (Reading, Mass.)
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Developing an effective AIDS vaccine requires preventing persistent human immunodeficiency virus type 1 (HIV-1) infection. Research focuses on neutralizing antibodies targeting the gp120 V3 domain to block initial viral entry and establish protective immunity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

    Vaccine·2015
    Same author

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants.

    Vaccine·2011
    Same author

    A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.

    Vaccine·2011
    Same author

    Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2008
    Same author

    Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

    Bioorganic & medicinal chemistry letters·2001
    Same author

    Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

    Bioorganic & medicinal chemistry letters·2001
    Same journal

    Global physiological controls.

    Biotechnology (Reading, Mass.)·1995
    Same journal

    Genetics of antibiotic production in Streptomyces coelicolor A3(2), a model streptomycete.

    Biotechnology (Reading, Mass.)·1995
    Same journal

    Isoprenoid antibiotics.

    Biotechnology (Reading, Mass.)·1995
    Same journal

    Agrocins.

    Biotechnology (Reading, Mass.)·1995
    Same journal

    Aminoglycosides and aminocyclitols (other than streptomycin).

    Biotechnology (Reading, Mass.)·1995
    Same journal

    Streptomycin and related aminoglycosides.

    Biotechnology (Reading, Mass.)·1995
    See all related articles

    Area of Science:

    • Immunology
    • Vaccinology
    • Virology

    Background:

    • Most vaccines prevent or reduce disease severity after pathogen exposure.
    • Antiviral immune responses in established human immunodeficiency virus type 1 (HIV-1) infections do not prevent long-term disease progression.
    • Preventing the establishment of persistent HIV-1 infection is crucial for a successful AIDS vaccine.

    Purpose of the Study:

    • To explore strategies for developing an AIDS vaccine that prevents persistent HIV-1 infection.
    • To investigate the role of humoral and cellular immune responses in preventing initial viral establishment.
    • To define the immunogenicity and effectiveness of various HIV-1 immunogens.

    Main Methods:

    • Studying chimpanzees as a model for HIV-1 infection.

    Related Experiment Videos

  • Focusing on humoral immune responses against the virus particle.
  • Analyzing virus-neutralizing antibodies targeting the gp120 envelope glycoprotein's third hypervariable (V3) domain.

    • Main Results:

    • Virus-neutralizing antibodies against the gp120 V3 domain may be effective in preventing HIV-1 infection in chimpanzees.
    • Research is defining the immunogenicity of envelope and core structural proteins.
    • The variability and conserved elements of the gp120 V3 domain are being characterized for immunogen design.

    Conclusions:

    • Preventing initial HIV-1 infection is a key goal for AIDS vaccine development.
    • Targeting the gp120 V3 domain with neutralizing antibodies shows promise.
    • Further studies on humoral and cellular responses against infected cells are essential for enhancing vaccine efficacy.